SK10552002A3 - Kombinácia a jej použitie - Google Patents

Kombinácia a jej použitie Download PDF

Info

Publication number
SK10552002A3
SK10552002A3 SK1055-2002A SK10552002A SK10552002A3 SK 10552002 A3 SK10552002 A3 SK 10552002A3 SK 10552002 A SK10552002 A SK 10552002A SK 10552002 A3 SK10552002 A3 SK 10552002A3
Authority
SK
Slovakia
Prior art keywords
mirtazapine
gepirone
combination
treatment
depression
Prior art date
Application number
SK1055-2002A
Other languages
English (en)
Slovak (sk)
Inventor
John Stuart Andrews
Wilhelmus Drinkenburg
Nicholas Matthew Ward
Original Assignee
Akzo Nobel N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel N.V. filed Critical Akzo Nobel N.V.
Publication of SK10552002A3 publication Critical patent/SK10552002A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK1055-2002A 2000-01-19 2001-01-15 Kombinácia a jej použitie SK10552002A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00200189 2000-01-19
PCT/EP2001/000407 WO2001052855A2 (en) 2000-01-19 2001-01-15 Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone

Publications (1)

Publication Number Publication Date
SK10552002A3 true SK10552002A3 (sk) 2002-12-03

Family

ID=8170928

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1055-2002A SK10552002A3 (sk) 2000-01-19 2001-01-15 Kombinácia a jej použitie

Country Status (21)

Country Link
US (2) US6835728B2 (ko)
EP (1) EP1251854A2 (ko)
JP (1) JP2003520237A (ko)
KR (1) KR20020068404A (ko)
CN (1) CN1223349C (ko)
AR (1) AR027240A1 (ko)
AU (1) AU780817B2 (ko)
BR (1) BR0107721A (ko)
CA (1) CA2396066A1 (ko)
CO (1) CO5261583A1 (ko)
HK (1) HK1047548A1 (ko)
HU (1) HUP0204050A3 (ko)
IL (1) IL150289A0 (ko)
MX (1) MXPA02007095A (ko)
NO (1) NO20023448L (ko)
PE (1) PE20011049A1 (ko)
PL (1) PL356605A1 (ko)
RU (1) RU2268725C2 (ko)
SK (1) SK10552002A3 (ko)
WO (1) WO2001052855A2 (ko)
ZA (1) ZA200205161B (ko)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
US20060122127A1 (en) * 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
PE20070523A1 (es) 2005-09-12 2007-06-28 Wyeth Corp Formulacion de liberacion sostenida del glucuronato de (8-{4-[3-(5-fluoro-1h-indol-3-il)-propil]-piperazin-1-il}-2-metil-4h-benzo[1,4]oxazin-3-ona
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
GT200600416A (es) 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
EP1792618A1 (en) * 2005-11-30 2007-06-06 Rainer Freynhagen R-mirtazapine for the treatment of pain
JP2009538334A (ja) * 2006-05-22 2009-11-05 ヴァンダ ファーマシューティカルズ インコーポレイテッド 抑うつ障害のための治療
TW200808804A (en) * 2006-05-22 2008-02-16 Organon Nv Mirtazapine for the treatment of neuropathic pain
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
CA2704117C (en) * 2007-11-02 2015-11-17 Acrux Dds Pty Ltd Transdermal delivery system
EP2576520A1 (en) 2010-05-28 2013-04-10 GE Healthcare UK Limited Radiolabeled compounds and methods thereof
GB201112987D0 (en) 2011-07-28 2011-09-14 Ge Healthcare Ltd Novel compound
CN108743593B (zh) * 2018-08-31 2019-03-26 程世宏 一种抗抑郁药物及其口服颗粒剂和制药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US4771053A (en) * 1987-03-02 1988-09-13 Bristol-Myers Company Method for alleviation of primary depressive disorders
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5011841B1 (en) * 1989-11-14 1994-09-06 Pfizer Treatment of depression
GB9303968D0 (en) 1993-02-26 1993-04-14 Wyeth John & Brother Ltd 5-ht1a ligands
GB9603136D0 (en) * 1996-02-15 1996-04-17 Merck Sharp & Dohme Therapeutic agents
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
IL123716A (en) * 1997-03-27 2001-03-19 Akzo Nobel Nv Therapeutic combinations of mirtazapine and an antipsychotic agent
ZA982368B (en) * 1997-03-27 1998-09-23 Akzo Nobel Nv New therapeutic combinations

Also Published As

Publication number Publication date
JP2003520237A (ja) 2003-07-02
RU2002122084A (ru) 2004-03-10
HUP0204050A2 (hu) 2003-03-28
AU780817B2 (en) 2005-04-21
US20050090488A1 (en) 2005-04-28
CO5261583A1 (es) 2003-03-31
AR027240A1 (es) 2003-03-19
PE20011049A1 (es) 2001-10-18
PL356605A1 (en) 2004-06-28
EP1251854A2 (en) 2002-10-30
AU2516201A (en) 2001-07-31
NO20023448D0 (no) 2002-07-18
CN1223349C (zh) 2005-10-19
RU2268725C2 (ru) 2006-01-27
KR20020068404A (ko) 2002-08-27
NO20023448L (no) 2002-09-17
CN1395486A (zh) 2003-02-05
CA2396066A1 (en) 2001-07-26
MXPA02007095A (es) 2003-04-14
HUP0204050A3 (en) 2004-09-28
WO2001052855A8 (en) 2002-12-27
WO2001052855A3 (en) 2002-01-10
WO2001052855A2 (en) 2001-07-26
BR0107721A (pt) 2002-10-01
IL150289A0 (en) 2002-12-01
US20030105083A1 (en) 2003-06-05
HK1047548A1 (zh) 2003-02-28
US6835728B2 (en) 2004-12-28
ZA200205161B (en) 2003-09-29

Similar Documents

Publication Publication Date Title
JP4249415B2 (ja) Ｃｎｓ疾患の治療のためのピロリジンアセトアミド誘導体単体又は組み合わせ物
US20050096311A1 (en) Compositions and methods for treatment of nervous system disorders
EP1994932A1 (en) Use of N-desmethylclozapine to treat human psychosis
US20080214592A1 (en) Methods of treating anxiety disorders
US20060122127A1 (en) Methods for reducing the side effects associated with mirtzapine treatment
SK10552002A3 (sk) Kombinácia a jej použitie
CA2500662A1 (en) Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
US9732059B2 (en) Methods of use of cyclic amide derivatives to treat schizophrenia
US20080004284A1 (en) Method for treating fibromyalgia syndrome and related conditions
KR100425045B1 (ko) 약물중독의치료를위한멜라토닌함유약학적조성물
WO1993021917A1 (en) Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia
US20180155318A1 (en) Methods of use of cyclic amide derivatives to treat schizophrenia
KR20100038120A (ko) 신경퇴행성 장애의 치료를 위한 신규한 네라멕산 조합물
SK284521B6 (sk) Použitie melatonínu na prípravu farmaceutického prostriedku
US6979698B1 (en) Method of treating cognitive deficits in learning and memory
Goldberg Sustained yawning as a side effect of imipramine
CN101028265A (zh) 一种改善睡眠调整睡醒节律的黑白药物组合物
WO2005097138A2 (en) Combinations comprising oxcarbazepine to treat affective disorders
CZ20022320A3 (cs) Kombinace účinných látek a její použití pro výrobu farmaceutického prostředku
CN1931153A (zh) 用于治疗抑郁症及相关病症的包括文拉法辛的药物组合物
Lahmeyer Pharmacology of sleep
WO2002016347A1 (en) Active metabolite of gepirone
Lindsey Effects of monoamine transporter blockers on cocaine self-administration: Relation to dopamine transporter occupancy measured by PET in rhesus monkeys. An investigation of substitute agonist therapeutic strategies for cocaine addiction
MXPA97005856A (en) Use of melatonine in the manufacture of unmedicament to deal with addiction to dro

Legal Events

Date Code Title Description
FC9A Refused patent application